Patents by Inventor Kazuhiko Kimachi
Kazuhiko Kimachi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11027005Abstract: A method for preparing a PRP conjugate having high storage stability and a method for producing a Hib conjugate vaccine are provided. A method for preparing PRP conjugate in accordance with the embodiments of the present invention is characterized by that the release of PRPs after preparing the PRP conjugate is suppressed by using PRP with a lowered molecular weight than native PRP for a coupling reaction between PRP and a carrier protein. Also, a Hib conjugate vaccine comprising as an antigen the PRP conjugate prepared by said method has excellent storage stability and maintain sufficient immunogenicity.Type: GrantFiled: October 11, 2017Date of Patent: June 8, 2021Assignee: KM BIOLOGICS CO., LTD.Inventors: Makoto Moriyama, Katsuhiko Fukada, Kazuhiko Kimachi, Yuki Mihara, Hiroshi Yonemura, Yoichiro Kino
-
Patent number: 10881723Abstract: The present invention relates to a vaccine containing fixed virus particles, wherein a summed fever response of three rabbits to the fixed virus particles in a pyrogen test is less than 80% based on a summed fever response of three rabbits to original virus particles of the fixed virus particles or corresponding inactivated virus particles.Type: GrantFiled: January 10, 2017Date of Patent: January 5, 2021Assignee: KM BIOLOGICS CO., LTD.Inventors: Hiroto Onuma, Yukari Tsurudome, Kazuyuki Ikeda, Ryo Yamaue, Kazuhiko Kimachi, Motoharu Abe, Akihiro Watanabe, Yuki Ohara
-
Publication number: 20200093915Abstract: The present invention provides a vaccine containing virus-like particles derived from virus particles having an envelope, in which a lipid-component content of the virus-like particles is reduced relative to a lipid-component content of the virus particles.Type: ApplicationFiled: November 18, 2019Publication date: March 26, 2020Applicant: KM Biologics Co., Ltd.Inventors: Kazuhiko Kimachi, Motoharu Abe, Kazuyuki Ikeda, Hiroto Onuma, Yukari Tsurudome, Daisuke Ikeno, Kiyoto Nishiyama, Tatsufumi Onchi, Yusuke Ooyama, Issay Asano, Ryoichi Kitano
-
Publication number: 20200046822Abstract: A method for preparing a PRP conjugate having high storage stability and a method for producing a Hib conjugate vaccine are provided. A method for preparing PRP conjugate in accordance with the embodiments of the present invention is characterized by that the release of PRPs after preparing the PRP conjugate is suppressed by using PRP with a lowered molecular weight than native PRP for a coupling reaction between PRP and a carrier protein. Also, a Hib conjugate vaccine comprising as an antigen the PRP conjugate prepared by said method has excellent storage stability and maintain sufficient immunogenicity.Type: ApplicationFiled: October 11, 2017Publication date: February 13, 2020Applicant: KM Biologics Co., Ltd.Inventors: Makoto MORIYAMA, Katsuhiko FUKADA, Kazuhiko KIMACHI, Yuki MIHARA, Hiroshi YONEMURA, Yoichiro KINO
-
Patent number: 10525122Abstract: The present invention provides a vaccine containing virus-like particles derived from virus particles having an envelope, in which a lipid-component content of the virus-like particles is reduced relative to a lipid-component content of the virus particles.Type: GrantFiled: July 15, 2015Date of Patent: January 7, 2020Assignee: KM Biologics Co., Ltd.Inventors: Kazuhiko Kimachi, Motoharu Abe, Kazuyuki Ikeda, Hiroto Onuma, Yukari Tsurudome, Daisuke Ikeno, Kiyoto Nishiyama, Tatsufumi Onchi, Yusuke Ooyama, Issay Asano, Ryoichi Kitano
-
Publication number: 20190000960Abstract: The present invention relates to a vaccine containing fixed virus particles, wherein a summed fever response of three rabbits to the fixed virus particles in a pyrogen test is less than 80% based on a summed fever response of three rabbits to original virus particles of the fixed virus particles or corresponding inactivated virus particles.Type: ApplicationFiled: January 10, 2017Publication date: January 3, 2019Inventors: Hiroto ONUMA, Yukari TSURUDOME, Kazuyuki IKEDA, Ryo YAMAUE, Kazuhiko KIMACHI, Motoharu ABE, Akihiro WATANABE, Yuki OHARA
-
Publication number: 20170196965Abstract: The present invention provides a vaccine containing virus-like particles derived from virus particles having an envelope, in which a lipid-component content of the virus-like particles is reduced relative to a lipid-component content of the virus particles.Type: ApplicationFiled: July 15, 2015Publication date: July 13, 2017Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Kazuhiko KIMACHI, Motoharu ABE, Kazuyuki IKEDA, Hiroto ONUMA, Yukari TSURUDOME, Daisuke IKENO, Kiyoto NISHIYAMA, Tatsufumi ONCHI, Yusuke OOYAMA, Issay ASANO, Ryoichi KITANO
-
Patent number: 8226958Abstract: A novel prophylactic/remedy for immunopathy is provided which is not neutralized by a neutralizing antibody to Staphylococcal enterotoxin B (SEB), known as one of superantigens, and may effectively act as a superantigen. A modified SEB having a reduced reactivity with a neutralizing antibody to SEB (anti-SEB antibody) and a prophylactic/remedy for immunopathy comprising as an active ingredient said modified SEB. The modified SEB of the present invention may be prepared with the evolutionary molecular engineering technique by introducing amino acid substitution in the amino acid sequence of SEB, especially at an epitope recognition site of the anti-SEB antibody in the amino acid sequence of SEB.Type: GrantFiled: March 25, 2004Date of Patent: July 24, 2012Assignees: Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Kowa Company, Ltd.Inventors: Toshihiro Nakashima, Takumi Sasaki, Kazuhiko Kimachi, Shigeki Kuwata, Tsukasa Nishihara, Atsuko Sakata, Masao Ohkuchi, Tomoyuki Koshi, Toshiyuki Edano
-
Publication number: 20070166331Abstract: A novel prophylactic/remedy for immunopathy is provided which is not neutralized by a neutralizing antibody to Staphylococcal enterotoxin B (SEB), known as one of superantigens, and may effectively act as a superantigen. A modified SEB having a reduced reactivity with a neutralizing antibody to SEB (anti-SEB antibody) and a prophylactic/remedy for immunopathy comprising as an active ingredient said modified SEB. The modified SEB of the present invention may be prepared with the evolutionary molecular engineering technique by introducing amino acid substitution in the amino acid sequence of SEB, especially at an epitope recognition site of the anti-SEB antibody in the amino acid sequence of SEB.Type: ApplicationFiled: March 28, 2003Publication date: July 19, 2007Applicants: Juridical Foundation The Chem-Sero-Therapeutic Research Institute, Kowa Company Ltd.Inventors: Toshihiro Nakashima, Takumi Sasaki, Kazuhiko Kimachi, Shigeki Kuwata, Tsukasa Nishihara, Atsuko Sakata, Masao Ohkuchi, Tomoyuki Koshi, Toshiyuki Edano
-
Publication number: 20060024322Abstract: A prophylactic/remedy for immunopathy for immunopathy comprising, as an active ingredient, modifications of Staphylococcal enterotoxin B (SEB) with substitution of at least one amino acid residues within the amino acid sequence of natural type SEB, or derivatives thereof, wherein the SEB modifications or derivatives thereof have inhibitory activity on T cell activation wherein they interact with specific V? component of T cell receptor (TCR) but are reduced in their immunological responsiveness to SEB without inducing elimination of T cells having specific V? component, the elimination being normally induced by natural type SEB or recombinant wild-type SEB.Type: ApplicationFiled: May 5, 2005Publication date: February 2, 2006Inventors: Takumi Sasaki, Kazuhiko Kimachi, Kenji Soejima, Yumi Kimura, Chikateru Nozaki, Yoshihide Fujiyama
-
Patent number: 6114143Abstract: A monoclonal antibody useful for clinical application which recognizes the conserved region of V3-PND region of glycoprotein antigen having a molecular weight of about 1.2.times.10.sup.5 daltons (gp120) on a coating membrane of human immunodeficiency virus (HIV) and which has an ability to neutralize a broad range of various HIV variants, or a fragment thereof, and the chimeric and humanized antibodies derived therefrom are provided. By using as an immunogen a plurality of peptides having PND-Tip region containing the highly conserved GPGR sequence within PND of HIV gp120, a monoclonal antibody having a neutralizing activity to many HIV variants can be prepared. By transplanting the gene fragment coding for the variable region of said monoclonal antibody or complementarity determining region (CDR) of said region to a human antibody gene, a chimeric antibody or a reshaped antibody having an anti-HIV neutralizing activity which are effective for clinical application can be obtained.Type: GrantFiled: September 11, 1995Date of Patent: September 5, 2000Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Yasuyuki Eda, Hiroaki Maeda, Keiichi Makizumi, Kouichi Shiosaki, Kiyoshi Osatomi, Kazuhiko Kimachi, Hirofumi Higuchi, Sachio Tokiyoshi
-
Patent number: 5880274Abstract: A Gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglobulin .lambda. chain; a gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglobulin .kappa. chain; a gene fragment which comprises a DNA sequence coding for the constant region of feline immunoglobulin .gamma.Type: GrantFiled: November 17, 1995Date of Patent: March 9, 1999Assignee: Juridical Foundation, The Chemo-Sero-Therapeutic Research InstituteInventors: Hiroaki Maeda, Yasuyuki Eda, Kazuhiko Kimachi, Yoichi Ono, Sachio Tokiyoshi
-
Patent number: 5852183Abstract: A gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of canine immunoglobulin lambda chain; a gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of canine immunoglobulin kappa chain; a gene fragment which comprises a DNA sequence coding for the constant region of canine immunoglobulin gamma chain; a recombinant DNA molecule coding for an amino acid sequence of a mouse-dog chimeric antibody which comprises a gene fragment coding for an amino acid sequence of a variable region of a mouse immunoglobulin and a gene fragment coding for an amino acid sequence of a constant region of a canine immunoglobulin wherein the latter gene fragment; a polypeptide of a mouse-dog chimeric antibody which is expressed from a cell transformed with an expression vector for cells wherein said recombinant DNA molecule cording for an amino acid sequence of the mouse-dog chimeric antibody is incorporated; a dog-mouse heterohybridoma whichType: GrantFiled: May 8, 1996Date of Patent: December 22, 1998Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Hiroaki Maeda, Yasuyuki Eda, Kazuhiko Kimachi, Yoichi Ono, Sachio Tokiyoshi
-
Patent number: 5785968Abstract: Anti-FCV (feline calicivirus) feline-type recombinant antibody effective for treatment, prevention and diagnosis of FCV infection and a gene fragment useful for preparation of said antibody are provided. Cell line 1D7 capable of producing a mouse monoclonal antibody having an excellent FCV-neutralizing activity was constructed and a gene fragment coding for the V region in charge of the FCV-specific binding of said antibody was obtained. This gene fragment and the gene coding for the constant region of the feline antibody are used to give a chimeric anti-FCV recombinant antibody. The obtained recombinant antibody is a novel antibody and is useful for the diagnosis, treatment and prevention of feline virus infections, particularly feline calicivirus infection, with high safety in administration into cats.Type: GrantFiled: March 1, 1993Date of Patent: July 28, 1998Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Kazuhiko Kimachi, Hiroaki Maeda, Kiyoto Nishiyama, Sachio Tokiyoshi, Yukinobu Tohya, Takeshi Mikami
-
Patent number: 5773247Abstract: The present invention relates to a gene fragment coding for a variable region of an antibody having a neutralizing activity against human immunodeficiency virus (HIV) and a process for preparing the same. A mouse-human chimeric antibody and a mouse-human reshaped antibody having a neutralizing activity against HIV can be prepared by obtaining a specific nucleotide sequence of a gene fragment coding for a variable region of H chain and L chain of an antibody having a neutralizing activity against HIV, and then artificially fusing DNAs synthesized based on these nucleotide sequences with a gene coding for a human immunoglobulin. The novel recombinant anti-HIV antibody of the present invention is useful for treatment and prevention of AIDS.Type: GrantFiled: July 14, 1995Date of Patent: June 30, 1998Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Hiroaki Maeda, Kazuhiko Kimachi, Yasuyuki Eda, Kouichi Shiosaki, Kiyoshi Osatomi, Sachio Tokiyoshi
-
Patent number: 5760185Abstract: An anti-FHV-1 recombinant antibody efficacious for treatment, prevention and diagnosis of feline herpes virus-1 (FHV-1) and a gene fragment useful for preparing the same are provided. A cell producing a mouse monoclonal antibody having an excellent neutralizing activity against FHV-1 was constructed, and a gene fragment coding for V region of said antibody responsible for the specific binding activity against FHV-1 was obtained. Using this gene fragment and a gene fragment coding for the constant region of a feline antibody, a chimeric anti-FHV-1 recombinant antibody is obtained.Type: GrantFiled: May 26, 1995Date of Patent: June 2, 1998Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Kazuhiko Kimachi, Hiroaki Maeda, Kiyoto Nishiyama, Sachio Tokiyoshi
-
Patent number: 5683891Abstract: A novel method for production of an exogenous protein is provided, the method being suitable for expression of an exogenous protein, especially a recombinant antibody etc., in an eucaryotic cell by utilizing a genetic recombination technique. That is, a novel method for production of an exogenous protein is provided which allows for culture of a cell in which an exogenous gene is introduced in a serum-free medium and an efficient production of an exogenous protein, by using, as a host cell for expression, a fused cell which is prepared by fusing a mouse myeloma and a lymphatic cell and which can be cultured in a serum-free medium.Type: GrantFiled: May 26, 1995Date of Patent: November 4, 1997Assignee: Juridical Foundation The Chemo-Sero Therapeutic Research InstituteInventors: Kiyoto Nishiyama, Yuji Ishikawa, Kazuhiko Kimachi, Hiroaki Maeda, Sachio Tokiyoshi
-
Patent number: 5593861Abstract: A gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of canine immunoglobulin lambda chain; a gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of canine immunoglobulin kappa chain; a gene fragment which comprises a DNA sequence coding for the constant region of canine immunoglobulin gamma chain; a recombinant DNA molecule coding for an amino acid sequence of a mouse-dog chimeric antibody which comprises a gene fragment coding for an amino acid sequence of a variable region of a mouse immunoglobulin and a gene fragment coding for an amino acid sequence of a constant region of a canine immunoglobulin; a polypeptide of a mouse-dog chimeric antibody which is expressed from a cell transformed with an expression vector for cells wherein said recombinant DNA molecule cording for an amino acid sequence of the mouse-dog chimeric antibody is incorporated; a dog-mouse heterohybridoma which produces canine immunoglobulin;Type: GrantFiled: September 15, 1994Date of Patent: January 14, 1997Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Hiroaki Maeda, Yasuyuki Eda, Kazuhiko Kimachi, Yoichi Ono, Sachio Tokiyoshi
-
Patent number: 5504198Abstract: A Gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglobulin .lambda. chain; a gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglobulin .kappa. chain; a gene fragment which comprises a DNA sequence coding for the constant region of feline immunoglobulin .gamma.Type: GrantFiled: May 23, 1994Date of Patent: April 2, 1996Assignee: Juridical Foundation the Chemo-Sero Therapeutic Research InstituteInventors: Hiroaki Maeda, Yasuyuki Eda, Kazuhiko Kimachi, Yoichi Ono, Sachio Tokiyoshi